REO 016

Intravenous Administration of REOLYSIN® in Combination with Paclitaxel and Carboplatin for Patients with Non-Small Cell Lung Cancer

In March 2009, Oncolytics announced that it had started patient enrollment in its US Phase II clinical trial using intravenous administration of REOLYSIN^® in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumors.

The primary objectives of the Phase II trial are to determine the objective response rate of REOLYSIN^®   in combination with paclitaxel and carboplatin in patients with metastatic or recurrent NSCLC with Kras or EGFR-activated tumors, and to measure progression-free survival at six months. The secondary objectives are to determine the median survival and duration of progression-free survival in patients, and to evaluate the safety and tolerability of REOLYSIN^® in combination with paclitaxel and carboplatin in this patient population.
 
 
Links:

• July 6, 2011: Phase II Study of Paclitaxel and Carboplatin in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Kras or EGFR-Activated Tumors (PDF)

• July 6, 2011: Oncolytics Biotech Inc. Collaborators Present Positive REOLYSIN^® Clinical Trial Results at the 14th World Conference on Lung Cancer (Press Release)

• March 12, 2009: Oncolytics Biotech Inc. Announces Start of Enrollment in US Phase II Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with Kras or EGFR-Activated Tumors (Press Release)

• September 2, 2008: Oncolytics Biotech Inc. Announces US Phase II Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with Kras or EGFR-Activated Tumor (Press Release)

• REO 016 on ClinicalTrials.gov (External Link)